Key facts
- Catalio Capital Management is a venture capital firm based in New York, New York with 59 tracked portfolio companies.
- Notable positions include OpenEvidence, Resilience (Blue Ash), Hippocratic AI, Freenome, Imperative Care.
- Private Market View records 1 deal participation by Catalio Capital Management.
- Catalio Capital Management’s most recent recorded investment was in Mar 2026, one of 20 in the last 12 months and 43 over two years.
- Catalio Capital Management has 1 fund on record, raising $325 across the 1 that report a size.
- The team roster lists 88 people.
About Catalio Capital Management
Founded in 2020, Catalio Capital Management is a venture capital firm based in Baltimore, Maryland. The firm seeks to invest in companies operating in the biomedical technology sector. The firm invests in various asset classes like private equity, private credit, and public equity. The firm employs a long bias, fundamental, bottom-up equity and long/short strategy to invest. The firm is a Registered Investment Adviser (RIA).
Registered with the SEC
Form ADV · 2026-03 · CRD 310374- Regulatory AUM
- $718.1M
- Private fund assets
- $1.4B
- Private funds
- 23 · 14 venture, 3 private equity, 1 hedge, 5 other
- Staff
- 30
- Registered office
- NEW YORK, NY
- SEC status
- Approved
Reports custody of client assets.
Source: SEC Investment Adviser Public Disclosure, Form ADV (registered as CATALIO CAPITAL MANAGEMENT, LP).
Free account
See the whole book
- ·The book's top 25 — of 59 recorded positions
- ·Every recorded deal — 1 rounds
- ·Watchlist + alerts for Catalio Capital Management's activity
Create free account
No card required
Portfolio, priced
59 companies · by our current valuations| Company | Industry | Valuation | First invested | Role |
|---|---|---|---|---|
| OpenEvidence | — | $12.0B | — | |
| Resilience (Blue Ash) | — | $9.4B | — | |
| Hippocratic AI | — | $3.5B | — | |
| Freenome | Decision/Risk Analysis | $2.2B | — | |
| Imperative Care | Surgical Devices | $1.6B | — | |
| Carbon Health | Other Healthcare Technology Systems | $1.3B | — | |
| Lila Sciences | — | $1.3B | — | |
| Enveda | — | $1.2B | — | |
| Parabilis Medicines | Drug Discovery | $920.0M | — | |
| Visby Medical | — | $866.0M | — | |
| DNA Script | Biotechnology | $659.7M | — | |
| Tessera Therapeutics | — | $650.0M | — | |
| Iambic | — | $648.0M | — | |
| Odyssey Therapeutics | Biotechnology | $638.2M | — | |
| SetPoint Medical | Therapeutic Devices | $480.0M | — | |
| + 44 more companies · a free account shows the top of the book | ||||
Recent deals
1 recordedFunds
1 recorded- Catalio Structured Opportunities Fund II2024$325
$325 raised across the 1 fund that report a size
Team
88 people on record — 82 with verified contacts
Partners, principals, and the people who answer a pitch. Pro members reveal contacts with credits.
Frequently asked
- What companies does Catalio Capital Management invest in?
- Catalio Capital Management has 59 recorded portfolio companies, including OpenEvidence, Resilience (Blue Ash), Hippocratic AI, Freenome.
- What is Catalio Capital Management's AUM?
- Catalio Capital Management manages approximately $2.0B in assets.
- Is Catalio Capital Management actively investing?
- Catalio Capital Management's most recent recorded investment was in Mar 2026, with 20 investments in the last 12 months.